New insulin report highlights how incentives benefit middlemen, harm patients
By Brian Newell | January 22, 2021
The Senate Finance Committee has released a new report detailing findings of their investigation into the role that market dynamics play in the pricing of insulins. The report conclusions further...
Read More
Key facts: The final rebate rule will be a positive change for patients
By Tom Wilbur | January 19, 2021
While drug middlemen are making billions of dollars in record profits at a time when millions of Americans are facing financial struggles, they are also suing to block the final rebate rule, a...
Read More
PhRMA submits comments on ways to refocus the 340B program on America’s vulnerable patients
By Nicole Longo | November 2, 2020
In response to the Request for Input on Modernizing the 340B Drug Pricing Program issued by Representative Greg Walden and Senator Lamar Alexander, PhRMA has outlined a number of commonsense ways...
Read More
Study finds middlemen excluded nearly 850 medicines from formularies this year
By Katie Koziara | September 17, 2020
A new study from Xcenda finds that from 2014 to 2020, the number of medicines excluded by at least one of the three largest pharmacy benefit managers (PBMs) from their standard formularies...
Read More
PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs
By Holly Campbell | March 3, 2020
Yesterday, PhRMA submitted comments on the Department of Health & Human Services’ (HHS) 2021 Notice of Benefit and Payment Parameters proposed rule. The proposed rule would hurt patients’ ability...
Read More
340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients
By Nicole Longo | August 20, 2019
Congress created the 340B program to help safety-net providers, like federally-funded safety net clinics, access discounts on prescription medicines for vulnerable or uninsured patients....
Read More
Five key facts about the market for insulins
By Holly Campbell | April 1, 2019
A century ago, patients were treated with animal insulins. Today, biopharmaceutical companies produce insulins that operate at the molecular level, more closely resembling insulin released...
Read More
The PBM story you haven’t heard: Hidden fees quadrupled in two years
By Robert Zirkelbach | March 20, 2019
In the ongoing conversation around the role of pharmacy benefit managers (PBMs) in the supply chain, a new report further illuminates incentives that tie PBM revenue to higher list prices for...
Read More
OptumRX: Sharing rebates with patients is “worth it”
By Holly Campbell | March 18, 2019
PhRMA has long advocated for sharing the $166 billion in rebates and discounts given by biopharmaceutical companies to the government, insurers, and pharmacy benefit managers (PBMs) with patients...
Read More
Event tomorrow: Making the biopharmaceutical supply chain work for patients
By Katie Koziara | May 2, 2018
In the U.S. health care system, the complex process of delivering medicines to patients is highly intermediated and involves many entities, including insurance companies, pharmacy benefit managers...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
